CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Topiramate

托吡酯 杂质对照品Topiramate Impurities

EP34 个杂质条目34 impurity entries

本页汇总 托吡酯 的 34 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 34 impurity reference standards of Topiramate with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 托吡酯(Topiramate)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesIn situ identification and quantification of genotoxic sulfonyl chloride impurity in topiramate (Topamax tablets) via LC-MS/MS
    MethodsX · 2025 · Thumbar H et al.  ·  PMID 40657209  ·  DOI
  2. 杂质研究Impurity studiesTopiramate: A Review of Analytical Approaches for the Drug Substance, Its Impurities and Pharmaceutical Formulations
    Journal of chromatographic science · 2016 · Pinto EC et al.  ·  PMID 26276847  ·  DOI
  3. 杂质研究Impurity studiesA new organic hydrophilic monolith stationary phase for HILIC - ELSD topiramate quantification and separation with its main polar impurities in infusion solutions
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026 · Andre C, Guillaume YC  ·  PMID 41422618  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous Determination of Lamotrigine, Oxcarbazepine, Lacosamide, and Topiramate in Rat Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
    International journal of analytical chemistry · 2022 · Qiu E et al.  ·  PMID 35321047  ·  DOI
  5. 分析方法Analytical MethodsCompounding and quality control of two pediatric topiramate pharmaceutical preparations
    Die Pharmazie · 2021 · Mékidèche T et al.  ·  PMID 33849699  ·  DOI

托吡酯 —— 原料药与杂质对照品Topiramate — drug substance & impurities

共 35 个条目(含原料药本体)35 items incl. the drug substance
Topiramate structure
EP原料药 APIAPI
托吡酯Topiramate
Topiramate
CAS No.97240-79-4
Chemical FormulaC12H21NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 1 (Topiramate EP Impurity A) structure
EPA
托吡酯杂质1(托吡酯EP杂质A)Topiramate Impurity 1 (Topiramate EP Impurity A)
Topiramate Impurity 1 (Topiramate EP Impurity A)
CAS No.20880-92-6
Chemical FormulaC12H20O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 2 (Topiramate EP Impurity B) structure
EPB
托吡酯杂质2(托吡酯EP杂质B)Topiramate Impurity 2 (Topiramate EP Impurity B)
Topiramate Impurity 2 (Topiramate EP Impurity B)
CAS No.876403-98-4
Chemical FormulaC17H30N2O9S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 3 (Topiramate EP Impurity C) structure
EPC
托吡酯杂质3 (托吡酯EP杂质C)Topiramate Impurity 3 (Topiramate EP Impurity C)
Topiramate Impurity 3 (Topiramate EP Impurity C)
CAS No.106881-41-8
Chemical FormulaC9H17NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 4 (Topiramate EP Impurity D) structure
EPD
托吡酯杂质4(托吡酯EP杂质D)Topiramate Impurity 4 (Topiramate EP Impurity D)
Topiramate Impurity 4 (Topiramate EP Impurity D)
CAS No.950603-46-0
Chemical FormulaC25H39NO15S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 5 (Topiramate EP Impurity E) structure
EPE
托吡酯杂质5(托吡酯EP杂质E)Topiramate Impurity 5 (Topiramate EP Impurity E)
Topiramate Impurity 5 (Topiramate EP Impurity E)
CAS No.6347-01-9
Chemical FormulaC6H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 6 structure
6
托吡酯杂质6Topiramate Impurity 6
Topiramate Impurity 6
CAS No.7660-25-5
Chemical FormulaC6H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 7 structure
7
托吡酯杂质7Topiramate Impurity 7
Topiramate Impurity 7
CAS No.150609-95-3
Chemical FormulaC12H19ClO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 8 structure
8
托吡酯杂质8Topiramate Impurity 8
Topiramate Impurity 8
CAS No.32785-90-3
Chemical FormulaC12H19ClO5
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 11 structure
11
托吡酯杂质11Topiramate Impurity 11
Topiramate Impurity 11
CAS No.97240-80-7
Chemical FormulaC13H23NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 12 structure
12
托吡酯杂质12Topiramate Impurity 12
Topiramate Impurity 12
CAS No.106881-42-9
Chemical FormulaC6H13NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 13 structure
13
托吡酯杂质13Topiramate Impurity 13
Topiramate Impurity 13
CAS No.58238-46-3
Chemical FormulaC9H16O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 14 structure
14
托吡酯杂质14Topiramate Impurity 14
Topiramate Impurity 14
CAS No.912456-61-2
Chemical FormulaC9H16O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 15 structure
15
托吡酯杂质15Topiramate Impurity 15
Topiramate Impurity 15
CAS No.851957-35-2
Chemical FormulaC9H17NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 16 structure
16
托吡酯杂质16Topiramate Impurity 16
Topiramate Impurity 16
CAS No.38029-84-4
Chemical FormulaC6H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 17 structure
17
托吡酯杂质17Topiramate Impurity 17
Topiramate Impurity 17
CAS No.10489-81-3
Chemical FormulaC6H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 18 (Fructose) structure
18
托吡酯杂质18 (果糖)Topiramate Impurity 18 (Fructose)
Topiramate Impurity 18 (Fructose)
CAS No.57-48-7
Chemical FormulaC6H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 19 structure
19
托吡酯杂质19Topiramate Impurity 19
Topiramate Impurity 19
CAS No.198215-60-0
Chemical FormulaC12H21NO9S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 20 structure
20
托吡酯杂质20Topiramate Impurity 20
Topiramate Impurity 20
CAS No.198215-62-2
Chemical FormulaC12H21NO9S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 21 structure
21
托吡酯杂质21Topiramate Impurity 21
Topiramate Impurity 21
CAS No.205249-06-5
Chemical FormulaC9H17NO6S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 22 structure
22
托吡酯杂质22Topiramate Impurity 22
Topiramate Impurity 22
CAS No.106881-35-0
Chemical FormulaC12H19N3O8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 23 structure
23
托吡酯杂质23Topiramate Impurity 23
Topiramate Impurity 23
CAS No.83541-86-0
Chemical FormulaC9H16O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 28 structure
28
托吡酯杂质28Topiramate Impurity 28
Topiramate Impurity 28
CAS No.205248-77-7
Chemical FormulaC14H25NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 30 structure
30
托吡酯杂质30Topiramate Impurity 30
Topiramate Impurity 30
CAS No.205249-19-0
Chemical FormulaC12H21NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 32 structure
32
托吡酯杂质32Topiramate Impurity 32
Topiramate Impurity 32
CAS No.40591-95-5
Chemical FormulaC12H21NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 34 structure
34
托吡酯杂质34Topiramate Impurity 34
Topiramate Impurity 34
CAS No.150609-97-5
Chemical FormulaC12H21NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 41 structure
41
托吡酯杂质41Topiramate Impurity 41
Topiramate Impurity 41
CAS No.106881-39-4
Chemical FormulaC12H21NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 47 structure
47
托吡酯杂质47Topiramate Impurity 47
Topiramate Impurity 47
CAS No.152192-29-5
Chemical FormulaC16H29NO8S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 48 structure
48
托吡酯杂质48Topiramate Impurity 48
Topiramate Impurity 48
CAS No.120238-48-4
Chemical FormulaC13H22O9S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 49 structure
49
托吡酯杂质49Topiramate Impurity 49
Topiramate Impurity 49
CAS No.53209-16-8
Chemical FormulaC14H24O9S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 50 structure
50
托吡酯杂质50Topiramate Impurity 50
Topiramate Impurity 50
CAS No.53209-14-6
Chemical FormulaC15H26O9S
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 51 structure
51
托吡酯杂质51Topiramate Impurity 51
Topiramate Impurity 51
CAS No.66900-93-4
Chemical FormulaC9H16O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 52 structure
52
托吡酯杂质52Topiramate Impurity 52
Topiramate Impurity 52
CAS No.25018-67-1
Chemical FormulaC12H20O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 53 structure
53
托吡酯杂质53Topiramate Impurity 53
Topiramate Impurity 53
CAS No.18604-28-9
Chemical FormulaC12H20O6
Purity>95%询价On request
10mg25mg50mg100mg
Topiramate Impurity 57 structure
57
托吡酯杂质57Topiramate Impurity 57
Topiramate Impurity 57
CAS No.205249-36-1
Chemical FormulaC12H19ClO8S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

托吡酯 —— 研究文献与合成路线Topiramate — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 托吡酯 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Topiramate. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Determination of topiramate and its degradation product in liquid oral solutions by high performance liquid chromatography with a chemiluminescent nitrogen detector
    Styslo-Zalasik M, Li W · Journal of pharmaceutical and biomedical analysis · 2005 · 被引 16cited 16
  2. Topiramate: A Review of Analytical Approaches for the Drug Substance, Its Impurities and Pharmaceutical Formulations
    Pinto EC, Dolzan MD, Cabral LM, et al. · Journal of chromatographic science · 2016 · 被引 10cited 10
  3. In situ identification and quantification of genotoxic sulfonyl chloride impurity in topiramate (Topamax tablets) via LC-MS/MS
    Thumbar H, Dhalani J, Patel H, et al. · MethodsX · 2025 · 被引 3cited 3
  4. Sensitive detection of topiramate degradation products by high-performance liquid chromatography/electrospray ionization mass spectrometry using ion-pairing reagents and polarity switching
    Pinto EC, Xu C, Cabral LM, et al. · Rapid communications in mass spectrometry : RCM · 2019 · 被引 5cited 5
  5. A new organic hydrophilic monolith stationary phase for HILIC - ELSD topiramate quantification and separation with its main polar impurities in infusion solutions
    Andre C, Guillaume YC · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026
  6. Determination of the inorganic degradation products sulfate and sulfamate in the antiepileptic drug topiramate by capillary electrophoresis
    Klockow-Beck A, Nick A, Geisshuesler S, et al. · Journal of chromatography. B, Biomedical sciences and applications · 1998 · 被引 5cited 5

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION AND PURIFICATION OF TOPIRAMATE
    WANG LUNG-HU, HUANG CHUN-TENG, CHAN HARDY · 公开号 EP2367836EP2367836 · 2011
  2. PROCESS FOR THE PREPARATION AND PURIFICATION OF TOPIRAMATE
    WANG LUNG-HU, HUANG CHUN-TENG, CHAN HARDY · 公开号 WO2011096934WO2011096934 · 2011
  3. AN IMPROVED PROCESS FOR THE MANUFACTURE OF TOPIRAMATE
    CHAWLA HARMANDER PAL SINGH, CHOWDHARY ANIL SHANKAR, PATEL SUHAS MAFATLAL, VYAS KAUSHAL RAMESHCHANDRA · 公开号 WO2007099388WO2007099388 · 2007
  4. Process for the preparation of topiramate
    ARVAI GEZA, GARACZI SANDOR, MATE ATTILA G, LUKACS FERENC, et al. · 公开号 US7414126US7414126 · 2008
  5. Process for the preparation of topiramate
    ARVAI GEZA, GARACZI SANDOR, MATE ATTILA G, LUKACS FERENC, et al. · 公开号 US2006040874US2006040874 · 2006

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

托吡酯 杂质谱研究要点Topiramate — impurity profiling notes

下面这些是拿到 托吡酯 的 35 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 35 impurity entries for Topiramate, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances